Epsilon Healthcare delivered record September-quarter customer receipts of A$3.9 million, while nine-month revenue reached A$11.5 million. The growth story is strengthening, but cash fell to A$997,000 and quarterly operating cash flow remained negative.
- September-quarter customer receipts of A$3.9 million, up 34% year on year
- Nine-month revenue of A$11.5 million, up 80%
- Epsilon Pharmacy reaches A$2.3 million annualised revenue
- Quarterly operating cash flow was negative A$500,000
- A$1.72 million in unused finance facilities remained available
Record receipts meet a tighter cash position
Epsilon Healthcare Limited (ASX:EPN) delivered another strong revenue quarter, but the cash flow statement supplies a necessary second headline: customer receipts climbed 34% year on year to A$3.9 million while cash on hand fell from A$1.286 million to A$997,000.
The September result extended a run of operational growth across contract manufacturing, clinics and pharmacy. Nine-month revenue reached A$11.5 million, an 80% increase on the corresponding period, which the company translates into an annualised run rate of about A$16 million. That run rate is an extrapolation from the quarter, not formal financial guidance, and the filing does not provide a quantified profitability forecast.
The latest figure builds on the company’s earlier expansion across its operating divisions, including the first pharmacy expansion, which earlier coverage said included a Newtown, Sydney community pharmacy and A$2.3 million of annualised pharmacy revenue within its first year.
CDMO pipeline remains the main growth engine
Epsilon’s onshore contract development and manufacturing organisation continued to benefit from new and expanded client contracts, broader manufacturing volumes and a growing pipeline of domestic and international opportunities. The company also invested in additional dosage-form capability during the quarter, with new dose-form revenue expected in the December quarter.
The international manufacturing push is connected to the UK and Europe manufacturing deal, which earlier coverage said involved a three-year agreement to manufacture medicinal cannabis products. In the current filing, Epsilon points to its Australian and European GMP licences as a platform for serving customers across regulated markets, but it does not quantify the contribution expected from the newer opportunity pipeline.
Pharmacy adds digital and physical capacity
Epsilon Pharmacy is now generating approximately A$2.3 million in annualised revenue, supported by increased use of its digital platform and a larger bricks-and-mortar customer base. The business launched a purpose-built patient portal covering ordering, dispensing workflows and patient management, and established its first full-service community pharmacy in Newtown.
Epsilon Clinics also reported sustained patient activity, repeat consultations and growth in its active patient base. Those operating indicators may support recurring revenue, although the filing does not disclose segment revenue, margins or patient numbers, leaving the financial contribution of each division difficult to assess from the quarterly report alone.
Working capital and funding remain the test
The cash flow figures temper the upbeat operating narrative. Net cash used in operating activities was A$500,000 for the quarter, while product manufacturing and operating costs reached A$2.087 million, staff costs A$1.006 million and administration and corporate costs A$1.179 million. The company also increased holdings of raw materials, active pharmaceutical ingredients and manufacturing consumables to support anticipated production requirements.
At quarter end, Epsilon had A$3.926 million drawn across its financing facilities and A$1.72 million of unused capacity. The drawn facilities include a secured A$2.1 million loan carrying interest at 18% a year, alongside other facilities with interest rates of up to 15%. The next quarterly report will therefore have to show more than rising receipts: investors will need evidence that commercial growth is beginning to convert into stronger operating cash flow and a less expensive funding profile.
Bottom Line?
Epsilon is scaling its healthcare platform quickly, but the next proof point is whether higher receipts can outpace working-capital needs, corporate costs and expensive debt.
Questions in the middle?
- Can the CDMO pipeline convert into signed contracts and recurring revenue at the pace implied by the company’s expansion plans?
- Will the pharmacy portal and Newtown site generate enough volume and operating leverage to justify further investment?
- How quickly can Epsilon reduce negative operating cash flow while funding inventory, new dosage forms and international growth?